October 14, 2019

Canadian researchers have made an important advancement in creating synthetic antibodies, which could hold the key for the body to repair itself.

The team at the University of Toronto has been working for more than a decade on developing synthetic antibodies for broad applications. The study was published in the journal eLife.

“This is a cool idea to engineer antibodies to mimic key growth factors known as Wnt proteins,” said Scott Jones, Vice President, Scientific Affairs at BioBridge Global. “Wnt proteins regulate stem and progenitor cells. These proteins play a fundamental role in development and tissue repair.”

October 7, 2019

It takes a rare blood type from a special group of donors to save an infant: It often is type O-negative and cytomegalovirus-negative.

Rare blood, rare donors

O-negative is the blood type that can be transfused to patients of all blood types, yet makes up only 7% of the population.

Cytomegalovirus (CMV) causes mild to no symptoms in healthy people. CMV is common, with over half of adults being exposed to it by age 40. However, its presence can cause health complications for these tiny patients.

Things done for safety

Two methods are used to remove the virus:

September 30, 2019

Scientists and organizations developing legitimate stem cell therapies are applauding a change in Google’s advertising policy that will block online ads for unapproved stem cell treatments.

The change prohibits Google advertising for therapies with no scientific basis, as well as ads for treatments based on scientific findings and those in early stages of clinical trials.

GenCure, a subsidiary of BioBridge Global, only works with stem cell researchers seeking approval for therapies through appropriate regulatory authorities, including the U.S. Food and Drug Administration.

September 23, 2019

Findings from space-based science on stem cells could aid in the development of cellular therapies, tissue engineering and other areas of regenerative medicine.

The low-gravity condition onboard the U.S. National Laboratory on the International Space Station (ISS) will provide an opportunity for the McGowan Institute for Regenerative Medicine (MIRM) at the University of Pittsburgh to investigate regenerative medicine and its effect on human health in a new way.

September 16, 2019

The U.S. Food and Drug Administration changed the field of cancer treatment in 2010 when it approved the first immunotherapy for patients with advanced-stage prostate cancer.

Manufactured by Dendreon, PROVENGE (sipuleucel-T) became the first therapeutic cancer vaccine of its kind, taking a patient’s immune cells and programming them to target and attack certain prostate cancer cells.

“Dendreon was ahead of its time when they started,” said Rogelio Zamilpa, Director of Cord Blood with GenCure, a subsidiary of San Antonio-based nonprofit BioBridge Global. “They were one of the pioneers in what is now referred to as cell therapy wherein you take a patient’s cells, reprogram them outside of the body, and then infuse them back into the patient.”